{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T05:21:29Z","timestamp":1773292889340,"version":"3.50.1"},"reference-count":23,"publisher":"International Research and Cooperation Association for Bio & Socio-Sciences Advancement (IRCA-BSSA)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["DD&amp;T"],"published-print":{"date-parts":[[2016]]},"DOI":"10.5582\/ddt.2016.01049","type":"journal-article","created":{"date-parts":[[2016,9,4]],"date-time":"2016-09-04T22:04:35Z","timestamp":1473026675000},"page":"195-200","source":"Crossref","is-referenced-by-count":3,"title":["Dividing phase-dependent cytotoxicity profiling of human embryonic lung fibroblast identifies candidate anticancer reagents"],"prefix":"10.5582","volume":"10","author":[{"given":"Yoshinori","family":"Inagaki","sequence":"first","affiliation":[{"name":"Laboratory of Microbiology, Graduate School of Pharmaceutical Sciences, The University of Tokyo"},{"name":"Hepato-Biliary-Pancreatic Surgery Division, Department of Surgery, Graduate School of Medicine, the University of Tokyo"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhiko","family":"Matsumoto","sequence":"additional","affiliation":[{"name":"Laboratory of Microbiology, Graduate School of Pharmaceutical Sciences, The University of Tokyo"},{"name":"Teikyo University Institute of Medical Mycology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Tang","sequence":"additional","affiliation":[{"name":"Hepato-Biliary-Pancreatic Surgery Division, Department of Surgery, Graduate School of Medicine, the University of Tokyo"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhisa","family":"Sekimizu","sequence":"additional","affiliation":[{"name":"Laboratory of Microbiology, Graduate School of Pharmaceutical Sciences, The University of Tokyo"},{"name":"Teikyo University Institute of Medical Mycology"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3542","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Pardee AB. A restriction point for control of normal animal cell proliferation. Proc Natl Acad Sci U S A. 1974; 71:1286-1290.","DOI":"10.1073\/pnas.71.4.1286"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Nakayama KI, Nakayama K. Ubiquitin ligases: Cell-cycle control and cancer. Nat Rev Cancer. 2006; 6:369-381.","DOI":"10.1038\/nrc1881"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Sherr CJ. Cancer cell cycles. Science. 1996; 274:1672-1677.","DOI":"10.1126\/science.274.5293.1672"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Wardill HR, Bowen JM, Gibson RJ. Chemotherapyinduced gut toxicity: Are alterations to intestinal tight junctions pivotal? Cancer Chemother Pharmacol. 2012; 70:627-635.","DOI":"10.1007\/s00280-012-1989-5"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Gribaudo G, Riera L, Rudge TL, Caposio P, Johnson LF, Landolfo S. Human cytomegalovirus infection induces cellular thymidylate synthase gene expression in quiescent fibroblasts. J Gen Virol. 2002; 83:2983-2993.","DOI":"10.1099\/0022-1317-83-12-2983"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Binkova B, Sram RJ. The genotoxic effect of carcinogenic PAHs, their artificial and environmental mixtures (EOM) on human diploid lung fibroblasts. Mutation research. 2004; 547:109-121.","DOI":"10.1016\/j.mrfmmm.2003.12.006"},{"key":"7","unstructured":"7. Coppock DL, Kopman C, Scandalis S, Gilleran S. Preferential gene expression in quiescent human lung fibroblasts. Cell Growth Differ. 1993; 4:483-493."},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Levi-Schaffer F, Kupietzky A. Mast cells enhance migration and proliferation of fibroblasts into an in vitro wound. Exp Cell Res. 1990; 188:42-49.","DOI":"10.1016\/0014-4827(90)90275-F"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Post S, Weng YC, Cimprich K, Chen LB, Xu Y, Lee EY. Phosphorylation of serines 635 and 645 of human Rad17 is cell cycle regulated and is required for G1\/S checkpoint activation in response to DNA damage. Proc Natl Acad Sci U S A. 2001; 98:13102-13107.","DOI":"10.1073\/pnas.231364598"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Smilenov LB, Mikhailov A, Pelham RJ, Marcantonio EE, Gundersen GG. Focal adhesion motility revealed in stationary fibroblasts. Science. 1999; 286:1172-1174.","DOI":"10.1126\/science.286.5442.1172"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. de Weger VA, Beijnen JH, Schellens JH. Cellular and clinical pharmacology of the taxanes docetaxel and paclitaxel--a review. Anticancer Drugs. 2014; 25:488-494.","DOI":"10.1097\/CAD.0000000000000093"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. La Porta CA. Cellular targets for anticancer strategies. Current drug targets. 2004; 5:347-355.","DOI":"10.2174\/1389450043345434"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Tsai CJ, Nussinov R. The molecular basis of targeting protein kinases in cancer therapeutics. Semin Cancer Biol. 2013; 23:235-242.","DOI":"10.1016\/j.semcancer.2013.04.001"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Liu L, Yu H, Huang X, Tan H, Li S, Luo Y, Zhang L, Jiang S, Jia H, Xiong Y, Zhang R, Huang Y, Chu CC, Tian W. A novel engineered VEGF blocker with an excellent pharmacokinetic profile and robust anti-tumor activity. BMC Cancer. 2015; 15:170.","DOI":"10.1186\/s12885-015-1140-1"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Chen J, Gao J. Advances in the study of molecularly targeted agents to treat hepatocellular carcinoma. Drug Discov Ther. 2014; 8:154-164.","DOI":"10.5582\/ddt.2014.01031"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Novio S, Freire-Garabal M, Nunez MJ. Target driven preclinical screening for new antimitotic chemotherapy agents. Curr Top Med Chem. 2014; 14:2263-2271.","DOI":"10.2174\/1568026614666141130093425"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Lytton J, Westlin M, Hanley MR. Thapsigargin inhibits the sarcoplasmic or endoplasmic reticulum Ca-ATPase family of calcium pumps. J Biol Chem. 1991; 266:17067-17071.","DOI":"10.1016\/S0021-9258(19)47340-7"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Thastrup O, Cullen PJ, Drobak BK, Hanley MR, Dawson AP. Thapsigargin, a tumor promoter, discharges intracellular Ca<sup>2+<\/sup> stores by specific inhibition of the endoplasmic reticulum Ca<sup>2+<\/sup>-ATPase. Proc Natl Acad Sci U S A. 1990; 87:2466-2470.","DOI":"10.1073\/pnas.87.7.2466"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Andersen TB, Lopez CQ, Manczak T, Martinez K, Simonsen HT. Thapsigargin--from Thapsia L. to mipsagargin. Molecules. 2015; 20:6113-6127.","DOI":"10.3390\/molecules20046113"},{"key":"20","unstructured":"20. Jackisch C, Hahm HA, Tombal B, McCloskey D, Butash K, Davidson NE, Denmeade SR. Delayed micromolar elevation in intracellular calcium precedes induction of apoptosis in thapsigargin-treated breast cancer cells. Clin Cancer Res. 2000; 6:2844-2850."},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Denmeade SR, Jakobsen CM, Janssen S, Khan SR, Garrett ES, Lilja H, Christensen SB, Isaacs JT. Prostate-specific antigen-activated thapsigargin prodrug as targeted therapy for prostate cancer. J Natl Cancer Inst. 2003; 95:990-1000.","DOI":"10.1093\/jnci\/95.13.990"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Janssen K, Horn S, Niemann MT, Daniel PT, Schulze-Osthoff K, Fischer U. Inhibition of the ER Ca<sup>2+<\/sup> pump forces multidrug-resistant cells deficient in Bak and Bax into necrosis. Journal of cell science. 2009; 122:4481-4491.","DOI":"10.1242\/jcs.055772"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Mahadevan NR, Rodvold J, Almanza G, Perez AF, Wheeler MC, Zanetti M. ER stress drives Lipocalin 2 upregulation in prostate cancer cells in an NF-\u03baB-dependent manner. BMC Cancer. 2011; 11:229.","DOI":"10.1186\/1471-2407-11-229"}],"container-title":["Drug Discoveries &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ddt\/10\/4\/10_2016.01049\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,7]],"date-time":"2022-07-07T18:54:34Z","timestamp":1657220074000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ddt\/10\/4\/10_2016.01049\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016]]},"references-count":23,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.5582\/ddt.2016.01049","relation":{},"ISSN":["1881-7831","1881-784X"],"issn-type":[{"value":"1881-7831","type":"print"},{"value":"1881-784X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016]]}}}